ArticleMicrobiology spectrum2024
Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies.Pathogens (Basel, Switzerland) · 2025Pooled it
- Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria-A Subgroup Analysis from the FORTRESS Study.Infectious diseases and therapy · 2026Article
- Clinical Distribution Characteristics and Antimicrobial Resistance Trends ofInfection and drug resistance · 2026Article
- Carbapenemase-directed therapy: optimizing antibiotic combinations against carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- In Vitro Evaluation of Fosfomycin Combinations Against Metallo-β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- A novel broad host range phage phiA85 displays a synergistic effect with antibiotics targeting carbapenem-resistantMicrobiology spectrum · 2025Article
- Antibiotic tolerance and persistence in clinical isolates ofMicrobiology spectrum · 2025Article
- Evaluation of ceftazidime/avibactam in combination with colistin against KPC-2-producingJAC-antimicrobial resistance · 2025Article
- Evaluation of the in vitro efficacy of antimicrobials against Enterobacterales with multiple carbapenemase enzymes.Iranian journal of microbiology · 2025Article
- Recent Advances in Understanding the Clinical Implications of Heterogeneous Drug Resistance inInfection and drug resistance · 2025Review
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection.Infection and drug resistance · 2025Article
- Clinical epidemiology and prognostic factors in patients with KPC-producingFrontiers in public health · 2025Article
- Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods.Antibiotics (Basel, Switzerland) · 2024Article
- Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae.Scientific reports · 2024Article
- Effect of SiHuangQingXinWan onFrontiers in pharmacology · 2024Article
- Effectiveness of antimicrobial agent combinations against carbapenem-producingFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the IMPORTANCE: Our study confirmed the efficacy of the combination CZA+MEM against KPC-producing and non-carbapenemase-producing strains. For metalloenzyme-producing strains, CZA+ATM demonstrated the most significant synergy. Additionally, CZA exhibited a notable synergy effect when combined with FOS. These combination therapies present promising new options for the treatment of CRKP infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.